The state of Florida currently has 52 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
Recruiting
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other t... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/02/2025
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida +1 locations
Conditions: Healthy
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
Recruiting
This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/25/2025
Locations: Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida
Conditions: Healthy Participants
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Recruiting
This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body wei... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
06/24/2025
Locations: Fortrea Clinical Research Unit, Daytona Beach, Florida +1 locations
Conditions: Healthy, Obesity
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Par... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
06/24/2025
Locations: K2 Medical Research - The Villages, Lady Lake, Florida +1 locations
Conditions: Alzheimer Disease, Healthy
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Recruiting
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, exclu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/24/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Liver Dysfunction, Healthy
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Recruiting
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/23/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy Participants
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
Recruiting
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2025
Locations: ERG - Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Hepatic Impairment, Healthy
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
Recruiting
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/16/2025
Locations: Cpmi /Id# 276490, Miami, Florida
Conditions: Healthy Volunteers
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
Recruiting
The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
06/12/2025
Locations: Advanced Pharma CR, LLC ( Site 0005), Miami, Florida +1 locations
Conditions: Healthy
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
Recruiting
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
Gender:
MALE
Ages:
Between 18 years and 85 years
Trial Updated:
06/11/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida
Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
Adding Polyphenol-rich Pulses to Daily Diet Improves Skin Health by Reshaping the Skin Microbiome
Recruiting
Skin health is influenced by the microbiome, lipids, oxidative stress, inflammation, and UV exposure. A 14-week trial with 50 women aged 45-65 will test if polyphenol-rich pulses improve skin health by affecting these factors. Using a white rice control diet, the study will measure skin parameters and analyze correlations with changes in lipids and microbiome, potentially proving the benefits of pulses.
Gender:
FEMALE
Ages:
Between 45 years and 65 years
Trial Updated:
06/09/2025
Locations: Food Science and Human Nutrition, Gainesville, Florida
Conditions: Healthy
A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)
Recruiting
The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of MK-1084 when it is given to people with RI and if people with RI can tolerate it.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/05/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida
Conditions: Healthy, Renal Impairment